Physician profile
Kevin Jackson
NPI 1538662374
$6,520.21
in general payments reported to CMS, 2019-2025
13 companies · $539 in 2025
The $539 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2021: $94.95 · 2022: $435 · 2023: $4,252 · 2024: $1,099 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,690 · Food and Beverage: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,690.00 |
| Food and Beverage | $1,199.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $4,172.86 | 2022-2024 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Glaukos Corporation | $914.65 | 2022-2025 | Ce-Marked Kxla System |
| Alcon Vision LLC | $422.51 | 2021-2025 | Clareon, Tryptyr, Hydrus Microstent |
| Tarsus Pharmaceuticals, INC. | $251.92 | 2024-2025 | Xdemvy |
| Merz Pharmaceuticals, LLC | $151.08 | 2024 | Xeomin |
| Sight Sciences, INC. | $126.86 | 2023 | Sion Surgical Instrument, Omni Surgical System |
| Apellis Pharmaceuticals, INC. | $116.19 | 2025 | Syfovre |
| Rayner Intraocular Lenses Limited | $104.80 | 2022 | |
| Allergan, INC. | $99.99 | 2019 | |
| Horizon Therapeutics Plc | $82.08 | 2022 | |
| Astellas Pharma US INC | $30.00 | 2024 | Izervay |
| Dompe US, INC. | $23.91 | 2025 | Oxervate |
| Davol INC. | $23.36 | 2025 | Arista |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.